Understanding what goes wrong in the brain before Alzheimer's symptoms emerge is one of the field's most consequential challenges. Mounting evidence suggests vascular breakdown — not just amyloid plaques — is among the earliest pathological events, and identifying its molecular drivers could open doors to pre-symptomatic intervention years before cognitive decline sets in.
Using one-month-old APP/PS1 transgenic mice — a model that recapitulates familial Alzheimer's genetics — researchers characterized early cerebrovascular deterioration at a striking level of molecular resolution. At this very young age, the animals already showed measurably reduced cerebral microvascular density and shortened average vessel length, alongside disrupted expression of blood-brain barrier (BBB) structural proteins. Transcriptomic profiling of cortical and microvascular tissue fractions identified 956 differentially expressed transcripts compared to wild-type controls, including 539 long non-coding RNAs (lncRNAs). From this dataset, core regulatory genes governing microvascular function were prioritized using protein-protein interaction network analysis and comparative functional genomics, ultimately culminating in a comprehensive competing endogenous RNA (ceRNA) network that maps how lncRNAs may sponge specific microRNAs to dysregulate downstream messenger RNA targets implicated in BBB integrity and vessel maintenance.
This work contributes to a growing paradigm that repositions cerebrovascular dysfunction — rather than neuronal amyloid or tau pathology alone — as a primary therapeutic target. The ceRNA framework is particularly notable because lncRNA-miRNA-mRNA axes are increasingly recognized as master rheostats of vascular biology. However, substantial caveats apply: this is an animal-only study using a genetically engineered mouse model that incompletely mirrors sporadic human Alzheimer's. The cohort is small, the findings are correlational, and ceRNA network predictions from multi-database miRNA target tools carry known false-positive rates. Replication in human cerebrovascular tissue and validation of individual lncRNA functions through loss-of-function experiments are essential next steps. As a mechanistic hypothesis-generator, this is incremental but directionally meaningful — particularly for researchers hunting druggable non-coding RNA targets in early AD.
